Jim Burns joined Ensoma from Locanabio, where he was CEO and director of the board from 2019-2023. Prior to Locanabio, Dr. Burns was CEO of Casebia Therapeutics and led the team in discovering new CRISPR/Cas9-based breakthrough therapeutics to treat blood disorders, blindness, and heart disease. Prior to Casebia, he spent the bulk of his career at Genzyme and Sanofi, where he held several leadership roles with increasing responsibility, including North America site head for R&D, where he coordinated R&D operations across key therapeutic areas. Dr. Burns is a former board member of MassBio and a member of the National Academy of Engineering. He also served as the industry representative for the U.S. Food and Drug Administration General Plastic Surgery Panel. Dr. Burns earned a Bachelor of Science degree in biology from Purdue University and Master of Science and doctorate degrees in bioengineering from the University of Illinois-Chicago, where his thesis work focused on drug delivery. Following his graduate studies, he was a postdoctoral researcher at the University of Florida.